{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:47:16Z","timestamp":1791406036495,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To estimate the incidence, prevalence and incidence-based mortality in patients with gynecologic sarcoma (GS), and described the trends of survival and initial treatments in the US by using the Surveillance, Epidemiology, and End Results (SEER) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>GS cases aged 20\u00a0years or older between 1975 and 2015 were identified from SEER 9 registries. Incidence, prevalence, and incidence-based mortality were estimated, all rates were age adjusted to the 2000 US standard population and presented as per 100,000 persons. Annual percentage change (APC) and average APC (AAPC) were calculated to describe the trends. In addition, stage distribution, cancer-specific survival (CSS) and initial treatment pattern over time were also reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall age-adjusted incidence of GS increased from 2.38 to 3.41 per 100,000 persons from 1975 to 2015, with an AAPC of 1.0 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), and the AAPC increased to 1.3 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) in the last decade. The incidence of population aged\u2009\u2265\u200955\u00a0years was three or more times than that of population aged 20\u201354\u00a0year from 1975 to 2015. Corpus and uterus GS was the main subtype, and it increased significantly during last three decades (an APC of 1.5). In addition, the prevalence of corpus and uterus GS increased mostly among all GSs. The incidence of GS with regional and distant stages increased pronouncedly, but not for local stage. GS cases showed increasing 3-year and 5-year CSS rates except for other sites GS. Approximately 87.7% GS cases received surgery during the first-course treatment, but the proportion decreased over years. In contrast, the proportion of receiving multiple treatment modalities increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The incidence of GS increased significantly with improved survival, which might due to the strategy of combination of multiple treatment. However, no obvious improvement on the early detection of GS was found, which should be facilitated to further improve the prognosis of GS.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12905-023-02161-1","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:04:41Z","timestamp":1673280281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trends in incidence, survival and initial treatments of gynecological sarcoma: a retrospective analysis of the United States subpopulation"],"prefix":"10.1186","volume":"23","author":[{"given":"Xi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changfang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"2161_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1066896920958120","volume":"29","author":"M Libertini","year":"2021","unstructured":"Libertini M, Hallin M, Thway K, et al. Gynecological sarcomas: molecular characteristics, behavior, and histology-driven therapy. Int J Surg Pathol. 2021;29:4\u201320.","journal-title":"Int J Surg Pathol"},{"key":"2161_CR2","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3802\/jgo.2020.31.e25","volume":"31","author":"A Albert","year":"2020","unstructured":"Albert A, Lee A, Allbright R, Vijayakumar S. Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes. J Gynecol Oncol. 2020;31:e25.","journal-title":"J Gynecol Oncol"},{"key":"2161_CR3","first-page":"e10283","volume":"12","author":"N Nama","year":"2020","unstructured":"Nama N, Cason FD, Misra S, et al. Carcinosarcoma of the uterus: a study from the surveillance epidemiology and end result (SEER) database. Cureus. 2020;12:e10283.","journal-title":"Cureus"},{"key":"2161_CR4","first-page":"7303","volume":"34","author":"N Bacalbasa","year":"2014","unstructured":"Bacalbasa N, Balescu I, Dima S, Popescu I. Ovarian sarcoma carries a poorer prognosis than ovarian epithelial cancer throughout all FIGO stages: a single-center case-control matched study. Anticancer Res. 2014;34:7303\u20138.","journal-title":"Anticancer Res"},{"issue":"Suppl 2","key":"2161_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ijgo.12613","volume":"143","author":"N Mbatani","year":"2018","unstructured":"Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51\u20138.","journal-title":"Int J Gynaecol Obstet"},{"key":"2161_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1159\/000494393","volume":"41","author":"P Mallmann","year":"2018","unstructured":"Mallmann P. Uterine sarcoma\u2013difficult to diagnose hard to treat. Oncol Res Treat. 2018;41:674.","journal-title":"Oncol Res Treat"},{"key":"2161_CR7","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","volume":"24","author":"D Berton-Rigaud","year":"2014","unstructured":"Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24:S55\u201360.","journal-title":"Int J Gynecol Cancer"},{"key":"2161_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","volume":"26","author":"M Hosh","year":"2016","unstructured":"Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer. 2016;26:1098\u2013104.","journal-title":"Int J Gynecol Cancer"},{"key":"2161_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/IGC.0000000000000443","volume":"25","author":"M Francis","year":"2015","unstructured":"Francis M, Dennis NL, Hirschowitz L, et al. Incidence and survival of gynecologic sarcomas in England. Int J Gynecol Cancer. 2015;25:850\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"2161_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.bpobgyn.2011.07.001","volume":"25","author":"N Magne","year":"2011","unstructured":"Magne N, Pacaut C, Auberdiac P, et al. Sarcoma of vulva, vagina and ovary. Best Pract Res Clin Obstet Gynaecol. 2011;25:797\u2013801.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2161_CR11","doi-asserted-by":"crossref","unstructured":"Wohlmuth, C, Wohlmuth-Wieser, I. Gynecologic malignancies in children and adolescents: how common is the uncommon? J Clin Med. 2021;10.","DOI":"10.3390\/jcm10040722"},{"key":"2161_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/COC.0b013e31826b98e4","volume":"37","author":"CH Kirsch","year":"2014","unstructured":"Kirsch CH, Goodman M, Esiashvili N. Outcome of female pediatric patients diagnosed with genital tract rhabdomyosarcoma based on analysis of cases registered in SEER database between 1973 and 2006. Am J Clin Oncol. 2014;37:47\u201350.","journal-title":"Am J Clin Oncol"},{"key":"2161_CR13","unstructured":"https:\/\/seer.cancer.gov\/icd-o-3\/sitetype.icdo3.20220429.pdf"},{"key":"2161_CR14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0973-1482.138197","volume":"10","author":"R Singh","year":"2014","unstructured":"Singh R. Review literature on uterine carcinosarcoma. J Cancer Res Ther. 2014;10:461\u20138.","journal-title":"J Cancer Res Ther"},{"key":"2161_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.gtc.2016.07.012","volume":"45","author":"C Arroyo-Johnson","year":"2016","unstructured":"Arroyo-Johnson C, Mincey KD. Obesity epidemiology worldwide. Gastroenterol Clin North Am. 2016;45:571\u20139.","journal-title":"Gastroenterol Clin North Am"},{"key":"2161_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ygyno.2010.11.039","volume":"121","author":"WB Growdon","year":"2011","unstructured":"Growdon WB, Roussel BN, Scialabba VL, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011;121:212\u20137.","journal-title":"Gynecol Oncol"},{"key":"2161_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tjog.2017.05.003","volume":"56","author":"S Kusunoki","year":"2017","unstructured":"Kusunoki S, Terao Y, Ujihira T, et al. Efficacy of PET\/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. Taiwan J Obstet Gynecol. 2017;56:508\u201313.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2161_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1470-2045(19)30595-9","volume":"21","author":"MM Koo","year":"2020","unstructured":"Koo MM, Swann R, McPhail S, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 2020;21:73\u20139.","journal-title":"Lancet Oncol"},{"key":"2161_CR19","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","volume":"20","author":"G Garg","year":"2010","unstructured":"Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer. 2010;20:888\u201394.","journal-title":"Int J Gynecol Cancer"},{"key":"2161_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ssu.2980100510","volume":"10","author":"PJ DiSaia","year":"1994","unstructured":"DiSaia PJ, Pecorelli S. Gynecological sarcomas. Semin Surg Oncol. 1994;10:369\u201373.","journal-title":"Semin Surg Oncol"},{"key":"2161_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ygyno.2005.09.017","volume":"100","author":"AL Jonson","year":"2006","unstructured":"Jonson AL, Bliss RL, Truskinovsky A, et al. Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol. 2006;100:561\u20134.","journal-title":"Gynecol Oncol"},{"key":"2161_CR22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/0284186X.2012.689111","volume":"51","author":"CG Trope","year":"2012","unstructured":"Trope CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51:694\u2013705.","journal-title":"Acta Oncol"},{"key":"2161_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.critrevonc.2017.12.009","volume":"122","author":"I Desar","year":"2018","unstructured":"Desar I, Ottevanger PB, Benson C, van der Graaf W. Systemic treatment in adult uterine sarcomas. Crit Rev Oncol Hematol. 2018;122:10\u201320.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2161_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/clinpract11040103","volume":"11","author":"S Kostov","year":"2021","unstructured":"Kostov S, Kornovski Y, Ivanova V, et al. New aspects of sarcomas of uterine corpus-a brief narrative review. Clin Pract. 2021;11:878\u2013900.","journal-title":"Clin Pract"},{"key":"2161_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11912-016-0552-7","volume":"18","author":"MJ Nathenson","year":"2016","unstructured":"Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18:68.","journal-title":"Curr Oncol Rep"},{"key":"2161_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCO.0000000000000753","volume":"33","author":"B Hanvic","year":"2021","unstructured":"Hanvic B, Ray-Coquard I. Gynecological sarcomas: literature review of 2020. Curr Opin Oncol. 2021;33:345\u201350.","journal-title":"Curr Opin Oncol"},{"key":"2161_CR27","first-page":"234","volume":"75","author":"J Hamanishi","year":"2017","unstructured":"Hamanishi J, Mandai M, Konishi I. Immune checkpoint (PD-1 and CTIA-4) signal inhibitors for gynecologic oncology; up to date. Nihon Rinsho. 2017;75:234\u201344.","journal-title":"Nihon Rinsho"},{"key":"2161_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejogrb.2019.11.006","volume":"244","author":"GU Kucukgoz","year":"2020","unstructured":"Kucukgoz GU, Kilic BE, Paydas S, Guzel AB, Gumurdulu D, Vardar MA. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol. 2020;244:51\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2161_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2021.09.014","volume":"163","author":"HI Ha","year":"2021","unstructured":"Ha HI, Cho SH, Lim J, et al. Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry. Gynecol Oncol. 2021;163:506\u201310.","journal-title":"Gynecol Oncol"},{"key":"2161_CR30","first-page":"243","volume":"35","author":"B Kozakiewicz","year":"2014","unstructured":"Kozakiewicz B, Dmoch-Gajzlerska E, Roszkowska-Purska K. Carcinomas and sarcomas of Bartholin gland: a report of nine cases and review of the literature. Eur J Gynaecol Oncol. 2014;35:243\u20139.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2161_CR31","unstructured":"https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2021\/treatment-limitations-nov2021.html"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T08:34:45Z","timestamp":1701678885000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02161-1","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study is a retrospective analysis of public dataset, no identified information of patients is used, hence the ethical approval for this study was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}